Gastroesophageal Junction Cancer

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

FDA label_change · 2020-03-19
FDA Approved: ONTRUZANT — Supplemental Application (Organon LLC)
FDA approves a supplemental application for ONTRUZANT (trastuzumab) filed by Organon LLC, resulting in changes to the product labeling.